![Medable partners with Masimo to bring wearable devices to clinical research and capture better data](https://hitconsultant.net/wp-content/uploads/2024/05/mightysat_rx_white_hand.png)
What you should know:
– Médable Inc., a leader in modern clinical trial technology, announced a groundbreaking partnership with Masimo (NASDAQ: MASI) to integrate medical-grade wearable devices into clinical research. This collaboration aims to streamline patient participation and improve data collection for clinical trials.
– By providing a patient-centered approach and fostering richer data collection, this collaboration holds promise for faster drug development, an improved patient experience, and ultimately advances in healthcare.
Alleviate patient burden
Masimo MightySat® Rx Pulse Oximeter, a trusted medical device used by clinicians around the world, is now integrated into the Medable platform. This eliminates the need for frequent, often tedious, travel to trial sites for routine testing, particularly beneficial for patients with serious illnesses like lung or breast cancer. More than 3,000 patients participating in eight major oncology trials conducted in 25 countries are already benefiting from this technology.
A multifaceted approach to data collection
The partnership goes beyond wearable devices. Medable's eCOA+ solution enables the capture of subjective data through human interaction. When combined with objective sensor data from Masimo, this creates a richer and more comprehensive data set for researchers. Medable specifically chose Masimo for its Signal Extraction Technology®, known for providing accurate readings even in harsh conditions.
Wearable devices gain traction in clinical trials
The use of wearables in clinical trials is increasing. Currently, 20% of trials using the Medable platform incorporate wearable devices, with 35% focused on oncology research. This trend highlights the growing recognition of the potential of wearables to improve patient experience and data collection.
Financial benefits of decentralized testing
Research from the Tufts Center for the Study of Drug Development further strengthens the case for decentralized trials. Their results suggest that decentralized trials can generate a net financial benefit of 5 to 13 times greater than Phase II and III trials, translating into a potential ROI of $10 million and $39 million respectively, with a average investment of $500,000 and $1.5 million for phases II and III. III, respectively.
“Medable has always been a leader in digital and decentralized clinical trials, so we are excited to work with a forward-thinking organization with the ambition and capacity to transform research,” said Dr. Daniel Cantillon, Chief Medical Officer by Masimo. “Clinical trials require world-class accuracy and data quality, both on-site and off-site, from clinical offices. Medable solves this problem through advocacy and allowing more patients to participate in research. Additionally, Medable's flexible platform enables scalability and data aggregation for a holistic approach.